Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2006 3
2007 3
2014 1
2018 1
2021 4
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Shimose S, Iwamoto H, Shirono T, Tanaka M, Niizeki T, Kajiwara M, Itano S, Yano Y, Matsugaki S, Moriyama E, Noda Y, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Shimose S, et al. Among authors: itano s. Cancer Med. 2023 Jun;12(11):12325-12335. doi: 10.1002/cam4.5931. Epub 2023 Apr 16. Cancer Med. 2023. PMID: 37062077 Free PMC article.
Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.
Shimose S, Hiraoka A, Tanaka M, Iwamoto H, Tanaka T, Noguchi K, Aino H, Yamaguchi T, Itano S, Suga H, Niizeki T, Moriyama E, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Kawaguchi T, Kuromatsu R, Koga H, Torimura T. Shimose S, et al. Among authors: itano s. Sci Rep. 2022 Oct 11;12(1):17018. doi: 10.1038/s41598-022-21528-2. Sci Rep. 2022. PMID: 36220865 Free PMC article.
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.
Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, Okamura S, Kamachi N, Suzuki H, Sakai M, Kajiwara A, Itano S, Tanaka M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T, On Behalf Of The Kurume Liver Cancer Study Group Of Japan. Iwamoto H, et al. Among authors: itano s. Cancers (Basel). 2021 Jun 3;13(11):2786. doi: 10.3390/cancers13112786. Cancers (Basel). 2021. PMID: 34205099 Free PMC article.
Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
Shimose S, Iwamoto H, Tanaka M, Niizeki T, Kajiwara M, Itano S, Moriyama E, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Shimose S, et al. Among authors: itano s. Cancers (Basel). 2022 Sep 1;14(17):4284. doi: 10.3390/cancers14174284. Cancers (Basel). 2022. PMID: 36077816 Free PMC article.
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study.
Sano T, Amano K, Ide T, Isoda H, Honma Y, Morita Y, Yano Y, Nakamura H, Itano S, Miyajima I, Shirachi M, Kuwahara R, Ohno M, Kawaguchi T, Tsutsumi T, Nakano D, Arinaga-Hino T, Kawaguchi M, Eguchi Y, Torimura T, Takahashi H, Harada M, Kawaguchi T; SAKS Study Group. Sano T, et al. Among authors: itano s. Hepatol Res. 2024 Apr;54(4):326-335. doi: 10.1111/hepr.13993. Epub 2023 Nov 28. Hepatol Res. 2024. PMID: 37975277
Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma.
Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Nomura T, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Ishihara A, Deguchi A, Arai H, Shimose S, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Aino H, Matsukuma N, Matsugaki S, Ogata K, Yano Y, Ueno T, Kajiwara M, Itano S, Fukuizumi K, Kawano H, Noguchi K, Tanaka M, Yamaguchi T, Kuromatsu R, Kawaguchi A, Koga H, Torimura T, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan. Iwamoto H, et al. Among authors: itano s. Cancers (Basel). 2021 Feb 5;13(4):646. doi: 10.3390/cancers13040646. Cancers (Basel). 2021. PMID: 33562793 Free PMC article.
First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Shimose S, Hiraoka A, Nakano M, Iwamoto H, Tanaka M, Tanaka T, Noguchi K, Aino H, Ogata K, Kajiwara M, Itano S, Yokokura Y, Yamaguchi T, Kawano H, Matsukuma N, Suga H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Kawaguchi T, Koga H, Torimura T. Shimose S, et al. Among authors: itano s. Cancer Med. 2021 Dec;10(23):8530-8541. doi: 10.1002/cam4.4367. Epub 2021 Oct 24. Cancer Med. 2021. PMID: 34693661 Free PMC article.
21 results